Press Releases

Reimagine Care and Memorial Hermann Health System Partner to Advance Cancer Care at Home

On Tuesday, July 25, Reimagine Care – the nation’s top cancer care service provider for at-home treatment – announced a brand-new partnership with Memorial Hermann Health System, based out of Houston, TX. The partnership will allow the companies to offer 24/7 care via phone, text, video, and in-home support from their wide variety of trained oncology medical professionals. Dr. Pallav Mehta, Medical Director for Reimagine Care, expressed his excitement about the partnership in Tuesday’s press release. “Reimagine Care looks to partner with innovative health care organizations...

Montage Health Selects Xealth to Drive Digital Health Strategy

Montage Health, a California-based non-profit network, announced on Tuesday that it has chosen the Xealth digital health platform as its new primary medical system. Known for its prominent role in the digital health space, Xealth provides a variety of services to its users including centralized medical technology, process automation, integration into existing healthcare workflows and more. “Montage Health works across our communities to keep people healthy and connected,” says Jill Reyes Tiongco, MD, FAMIA, chief medical information officer of Montage Health. Dr. Tiongco went on to...

Reimagine Care Welcomes Dan Nardi, Healthcare Industry Leader, as New CEO

Reimagine Care has announced that Dan Nardi will serve as its new Chief Executive Officer, effective July 10, 2023. Nardi replaces co-founder Dr. Aaron Gerber as CEO. Previously, Nardi served as Carrum Health’s Chief Operating Officer and Livongo’s Vice President of Operations. He brings to the role a deep understanding of value-based care and operational expertise. “I am extremely excited to join the leadership team of such an amazing organization that is changing the world for the better. As an organization with an impressive reputation, highly experienced...

Clinical ink Appoints Andrew Kraus as Chief Technology Officer

Clinical Ink, a global life science technology company, has announced the appointment of Andrew Kraus as chief technology officer. In this role, Kraus will lead the development of the company’s expanding technology portfolio to support clinical trials. Kraus is an accomplished global healthcare executive with a 30-year track record of successful innovation in clinical trials, leveraging his background in technology, strategy, operations, and finance. Prior to Clinical Ink, Kraus served as chief operating officer for World Care Clinical, a contract research organization (CRO) providing centralized imaging...

McKesson Ventures’ Dave Schulte Named One of Healthcare’s Top 25 Investors

McKesson Ventures Managing Director Dave Schulte has been recognized by GrowthCap as one of the top 25 healthcare investors for 2023. This award acknowledges healthcare investors who have demonstrated high levels of sustained investment performance and who are recognized as leaders by portfolio company CEOs, industry peers, and colleagues. For 20 years, Schulte has been investing in innovative healthcare technology and services businesses focused on improving data insights, health outcomes, and access to care. He joined McKesson Ventures as a managing director in 2014 after 10...

Koneksa Announces Partnership with Beacon Biosignals for Clinical Trials in Sleep and Neurologic Disorders Using EEG Biomarkers

Koneksa has announced a partnership with Beacon Biosignals, a computational neurodiagnostics company, to launch a clinical trial to investigate the integration of Beacon’s at-home electroencephalogram (EEG) into the Koneksa Neuroscience Solution Toolkit. The Beacon platform unlocks longitudinal, at-home EEG technology, applies machine-learning algorithms to maximize insights into brain activity, and empowers sponsors with comprehensive data analysis and data visualization capabilities. The Koneksa-sponsored clinical validation study, “A basket observational study to determine usability, analytical validity, clinical validity, and biomarker discovery for at-home EEG, wearable, and mobile device...

Xealth Is Honored In 25th Anniversary Digital Health Awards®

McKesson Ventures portfolio company Xealth was selected as a winner in the 25th anniversary Digital Health Awards® program. This competition recognizes the best digital health resources. “Shaping Your Digital Health Future” received a Gold Award for Connected Digital Health: Consumer Directed Digital Health Programs. “Digital solutions are becoming an integral part of care delivery and Xealth is the only digital health platform that takes an approach that has driven improved activation, engagement, and operational efficiency for our health system clients,” said Xealth Co-Founder and CEO Mike McSherry....

RxLightning Closes $17.5M Series A to Accelerate Growth and Remove Barriers to Essential Specialty Medications

McKesson Ventures has participated in a $17.5 million Series A round for RxLightning, a platform for streamlining access and affordability for specialty medications. This brings the total the company has raised since its inception to $20.5 million. With RxLightning, healthcare providers—from those practicing at independent clinics to large health systems—leverage a streamlined workflow to complete the multi-step specialty medication onboarding process in a matter of minutes. The company’s MedAccess Ecosystem is an integrated platform that provides transparency into the patient access and affordability journey for doctors,...

Aster Insights Announces that The University of Kansas Cancer Center will join the Oncology Research Information Network (ORIEN)

Aster Insights, a provider of technology-enabled data and analytics solutions for oncology discovery, has announced that The University of Kansas Cancer Center will join its Oncology Research Information Exchange Network (ORIEN). The KU Cancer Center is the latest NCI-designated cancer center to join ORIEN, which is comprised of 18 cancer centers across the U.S. dedicated to collaborative research to accelerate cancer discovery and development. Launched in 2014, Aster Insights’ ORIEN platform is the largest and longest-running academic cancer research consortium of its kind in the United...

ORIEN Member Presentations at 2023 ASCO Demonstrate Unique Value of Aster Insights’ Data

Aster Insights has announced its participation as a research partner at the American Society of Clinical Oncology (ASCO) Annual Meeting June 2-6, 2023, in Chicago. An oral presentation and three posters will be presented at this year’s ASCO meeting, utilizing the lifetime patient-consented longitudinal clinicogenomic data from the company’s Oncology Research Information Exchange Network® (ORIEN) AVATAR program. These presentations highlight the research partnerships and collaboration of Aster Insights and 18 premier cancer centers that comprise ORIEN. “We are thrilled to be selected for these diverse presentations...